Mounjaro contains tirzepatide, the first medicine to activate both the GIP and GLP-1 receptors
If approved, it would become the worlds first oral GLP-1 therapy specifically indicated for weight loss
This engagement stimulates the release of insulin, inhibits glucagon secretion, delays gastric emptying, and enhances a feeling of fullness, collectively contributing to improved glycemic control and weight loss
More about the medicines GLP-1 receptor agonists 1,2,3,4,5 act in the same way as GLP-1 (a natural hormone in the body), by increasing the amount of insulin that the pancreas releases in response to food
Portable medication fridges are also available and provide consistent temperature control for extended trips or business travel where access to standard refrigeration is limited
The side effects that seem overwhelming in month 2 become distant memories by month 6